Laura van Iersel

Laura van Iersel

Auto-generated profile, based on publicly available information

Laura van Iersel

Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center Utrecht , Utrecht , The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
LILaura van Iersel
Laura van Iersel
KBKaren E Brokke
Karen E Brokke
RARoger A H Adan
Roger A H Adan
LBLauren C M Bulthuis
Lauren C M Bulthuis
EAErica L T van Den Akker
Erica L T van Den Akker
HSHanneke M. Van Santen
Hanneke M. Van Santen
The development of hypothalamic obesity (HO) following craniopharyngioma (CP) and other suprasellar tumors leads to reduced patient quality of life. No treatment algorithms are currently available for management of HO. Depending on which hypothalamic nuclei are destroyed, the pathophysiologic mechanisms and clinical symptoms that contribute to HO differ among patients. Here, we review the contribution of the hypothalamus to the pathophysiologic mechanisms and symptoms underlying CP-associated HO. In addition, we performed a systematic search of MEDLINE and Embase to identify all intervention studies for weight management in patients with CP or other suprasellar tumors published until September 2017. The search yielded 1866 publications, of which 40 were included. Of these 40 studies, we identified four modalities for intervention (i.e., lifestyle, dietary, pharmacotherapeutic, or surgical) within six clinical domains (i.e., psychosocial disorders, hyperphagia, sleep disturbances, decreased energy expenditure, hyperinsulinemia, and hypopituitarism). We used the findings from our systematic review, in addition to current knowledge on the pathophysiology of HO, to develop an evidence-based treatment algorithm for patients with HO caused by CP or other suprasellar tumors. Although the individual effects of the HO interventions were modest, beneficial individual effects may be achieved when the pathophysiologic background and correct clinical domain are considered. These two aspects can be combined in an individualized treatment algorithm with a stepwise approach for each clinical domain. Recently elucidated targets for HO intervention were also explored to improve future management of HO for patients with CP and other suprasellar tumors.

1 December 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LILaura van Iersel
Laura van Iersel
ZLZhenghong Li
Zhenghong Li
DSDeo Kumar Srivastava
Deo Kumar Srivastava
TBTara M Brinkman
Tara M Brinkman
KBKari L Bjornard
Kari L Bjornard
WCWassim Chemaitilly
Wassim Chemaitilly
Context: Data on hypothalamic-pituitary (HP) disorders in systematically evaluated childhood cancer survivors are limited. Objective: To describe prevalence, risk factors, and associated adverse health outcomes of deficiencies in GH deficiency (GHD), TSH deficiency (TSHD), LH/FSH deficiency (LH/FSHD), and ACTH deficiency (ACTHD), and central precocious puberty (CPP). Design: Retrospective with cross-sectional health outcomes analysis. Setting: Established cohort; tertiary care center. Patients: Participants (N = 3141; median age, 31.7 years) were followed for a median 24.1 years. Main Outcome Measure: Multivariable logistic regression was used to calculate ORs and 95% CIs for associations among HP disorders, tumor- and treatment-related risk factors, and health outcomes. Results: The estimated prevalence was 40.2% for GHD, 11.1% for TSHD, 10.6% for LH/FSHD, 3.2% for ACTHD, and 0.9% for CPP among participants treated with HP radiotherapy (n = 1089), and 6.2% for GHD, and 30 Gy for ACTHD), alkylating agents (GHD, LH/FSHD), intrathecal chemotherapy (GHD), hydrocephalus with shunt placement (GHD, LH/FSHD), seizures (TSHD, ACTHD), and stroke (GHD, TSHD, LH/FSHD, ACTHD). Adverse health outcomes independently associated with HP disorders included short stature (GHD, TSHD), severe bone mineral density deficit (GHD, LH/FSHD), obesity (LH/FSHD), frailty (GHD), impaired physical health-related quality of life (TSHD), sexual dysfunction (LH/FSHD), impaired memory, and processing speed (GHD, TSHD). Conclusion: HP radiotherapy, central nervous system injury, and, to a lesser extent, chemotherapy are associated with HP disorders, which are associated with adverse health outcomes.

20 November 2021 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
LILaura van Iersel
Laura van Iersel
RMRenee L Mulder
Renee L Mulder
CDChristian Denzer
Christian Denzer
LCLaurie E Cohen
Laurie E Cohen
HSHelen A Spoudeas
Helen A Spoudeas
HSHanneke M. Van Santen
Hanneke M. Van Santen
Endocrine disorders in survivors of childhood, adolescent, and young adult (CAYA) cancers are associated with substantial adverse physical and psychosocial effects. To improve appropriate and timely endocrine screening and referral to a specialist, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) aims to develop evidence and expert consensus-based guidelines for healthcare providers that harmonize recommendations for surveillance of endocrine disorders in CAYA cancer survivors. Existing IGHG surveillance recommendations for premature ovarian insufficiency, gonadotoxicity in males, fertility preservation, and thyroid cancer are summarized. For hypothalamic-pituitary (HP) dysfunction, new surveillance recommendations were formulated by a guideline panel consisting of 42 interdisciplinary international experts. A systematic literature search was performed in MEDLINE (through PubMed) for clinically relevant questions concerning HP dysfunction. Literature was screened for eligibility. Recommendations were formulated by drawing conclusions from quality assessment of all evidence, considering the potential benefits of early detection and appropriate management. Healthcare providers should be aware that CAYA cancer survivors have an increased risk for endocrine disorders, including HP dysfunction. Regular surveillance with clinical history, anthropomorphic measures, physical examination, and laboratory measurements is recommended in at-risk survivors. When endocrine disorders are suspected, healthcare providers should proceed with timely referrals to specialized services. These international evidence-based recommendations for surveillance of endocrine disorders in CAYA cancer survivors inform healthcare providers and highlight the need for long-term endocrine follow-up care in subgroups of survivors and elucidate opportunities for further research.

4 January 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LILaura van Iersel
Laura van Iersel
RMRuud W.H. Meijneke
Ruud W.H. Meijneke
AMAntoinette Y.N. Schouten‐Van Meeteren
Antoinette Y.N. Schouten‐Van Meeteren
LRLiesbeth Reneman
Liesbeth Reneman
MWMaartje M. de Win
Maartje M. de Win
HSHanneke M. Van Santen
Hanneke M. Van Santen

18 January 2018 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
LILaura van Iersel
Laura van Iersel
HSHanneke M. Van Santen
Hanneke M. Van Santen
GZGladys R.J. Zandwijken
Gladys R.J. Zandwijken
NZNitash Zwaveling-Soonawala
Nitash Zwaveling-Soonawala
AHAnita C.S. Hokken-Koelega
Anita C.S. Hokken-Koelega
ATA.S. Paul van Trotsenburg
A.S. Paul van Trotsenburg
Background: Growth hormone (GH) treatment may unmask central hypothyroidism (CeH). This was first observed in children with GH deficiency (GHD), later also in adults with GHD due to acquired “organic” pituitary disease. We hypothesized that newly diagnosed CeH in children after starting GH treatment for nonacquired, apparent isolated GHD points to congenital “organic” pituitary disease. Methods: Nationwide, retrospective cohort study including all children with nonacquired GHD between 2001 and 2011 in The Netherlands. The prevalence of CeH, hypothalamic-pituitary (HP) abnormalities, and neonatal congenital hypothyroidism screening results were evaluated. Results: Twenty-three (6.3%) of 367 children with apparent isolated GHD were prescribed LT4 for presumed CeH within 2 years after starting GH treatment. Similarly to children already diagnosed with multiple pituitary hormone deficiency, 75% of these 23 had structural HP abnormalities. In children not prescribed LT4, low pre- or post-GH treatment FT4 concentrations were also associated with structural HP abnormalities. Neonatal screening results of only 4 of the 23 children could be retrieved. Conclusion: In children with nonacquired, apparent isolated GHD, a diagnosis of CeH after, or a low FT4 concentration around the start of GH treatment, is associated with congenital structural HP abnormalities, i.e., “organic” pituitary disease. Neonatal values could not be judged reliably.

1 November 2018 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
LILaura van Iersel
Laura van Iersel
ZLZhenghong Li
Zhenghong Li
WCWassim Chemaitilly
Wassim Chemaitilly
LSLeslie R. Schover
Leslie R. Schover
KNKirsten K. Ness
Kirsten K. Ness
JKJames L. Klosky
James L. Klosky
This survey study evaluates the presence of erectile dysfunction in men who had experienced cancer during childhood.